| Literature DB >> 31178352 |
Samanta Antonella Mariani1, Zhuan Li2, Siobhan Rice2, Carsten Krieg3, Stamatina Fragkogianni4, Mark Robinson5, Chris Sebastiaan Vink2, Jeffrey William Pollard4, Elaine Dzierzak6.
Abstract
Hematopoietic stem cells (HSCs) are generated from specialized endothelial cells of the embryonic aorta. Inflammatory factors are implicated in regulating mouse HSC development, but which cells in the aorta-gonad-mesonephros (AGM) microenvironment produce these factors is unknown. In the adult, macrophages play both pro- and anti-inflammatory roles. We sought to examine whether macrophages or other hematopoietic cells found in the embryo prior to HSC generation were involved in the AGM HSC-generative microenvironment. CyTOF analysis of CD45+ AGM cells revealed predominance of two hematopoietic cell types, mannose-receptor positive macrophages and mannose-receptor negative myeloid cells. We show here that macrophage appearance in the AGM was dependent on the chemokine receptor Cx3cr1. These macrophages expressed a pro-inflammatory signature, localized to the aorta, and dynamically interacted with nascent and emerging intra-aortic hematopoietic cells (IAHCs). Importantly, upon macrophage depletion, no adult-repopulating HSCs were detected, thus implicating a role for pro-inflammatory AGM-associated macrophages in regulating the development of HSCs.Entities:
Keywords: AGM; CD206; Csf1r; Cx3cr1; MacGreen; hematopoietic development; hematopoietic stem cell; inflammation; macrophage; mannose receptor
Mesh:
Substances:
Year: 2019 PMID: 31178352 PMCID: PMC6591003 DOI: 10.1016/j.immuni.2019.05.003
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745
Figure 1CyTOF Analysis of CD45+ AGM, Yolk Sac, and Adult Spleen Cells
(A) tSNE clusters indicated by color (12 with >10 cells) of CD45+ E10 AGM (top), E10 YS (middle) (n = 31, 31–37 sp) and adult spleen (bottom) cells based on 21 cell-surface markers.
(B) Heatmaps of surface-marker expression in CD45+ AGM (top), YS (middle), and spleen (bottom) cells with percentages of cells in each tSNE cluster and lineage phenotype: N, neutrophils; M, macrophage and macrophage progenitor; L, lymphocytes and lymphoid progenitors, P, multipotential progenitor.
Figure 2Appearance and Localization of AGM Myeloid Cells
(A and B) Flow cytometric analysis of E8.5 to E11.5 MacGreen (A) AGM and (B) YS cells. Percentage of GFP+ cells (top), CD45+ cells in GFP+ fraction (middle), and CD11b+F4/80+ cells in CD45+ fraction (bottom). Mean + SEM (n = 3/time, 2–4 AGM, 2–3 YS). ND, not done. One-way Anova with Bonferroni correction.
(C) Maximum projection confocal image of whole-mount E10 MacGreen embryo showing the trunk. A, aorta; V, vitelline artery. CD31+ endothelium, gray; macrophages, green; c-Kit+ IAHCs, magenta. Scale bar, 200 μm. High-magnification images of IAHC (right). Scale bars, 20 μm.
(D) Immunofluorescence of E10.5 MacGreen embryo transverse cryosection (10 μm) through aorta. AGM, aorta-gonad-mesonephros; NT, neural tube; S, somites. Yellow line, spatial boundaries of AGM. CD34+ endothelium is in magenta, macrophages in green, and nuclei in blue (DAPI). Scale bar, 100 μm.
(E) Total number of macrophages per μm2 in non-hematopoietic tissues of trunk (non-AGM) and AGM region. n = 40 (10 random sections, 4 embryos). The data are represented as mean + SEM. One-way Anova with Dunnett post-hoc test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. See Figures S3 and S4.
Figure 3Macrophage Recruitment to the AGM is Cx3cr1 Mediated
(A and B) Cytofluorimetric analysis of chemokine receptors on (A) AGM and (B) YS macrophages of E10 and E10.5 MacGreen embryos. GeoMean over FMO (fluorescence minus one). Bars represent mean + SEM (n = 3, 2–3 AGM or YS/experiment).
(C) Semi-quantitative RT-PCR analysis of Ccl2, Ccl11, Ccl3, Cxcl12, and Cx3cl1 in CD31+ cells of E10.5 MacGreen AGM. Data are fold-change over the expression in GFP+ cells, set as one (horizontal line). Bars represent mean + SEM (n = 3).
(D and E) Semi-quantitative RT-PCR analysis of (D) Cxcl12 and (E) Cx3cl1 in E10.5 Ly6A-GFP embryos. Data normalized to CD31+ cells. Bars represent mean + SEM (n = 3).
(F) Cytofluorimetric percentages of macrophages (CD45+c-Kit−CD11b+F4/80+) in AGM (left) and YS (right) of E10.5 Cx3cr1+/+ wild type, Cx3cr1gfp/+, and Cx3cr1gfp/gfp embryos. Each symbol is an individual embryo. Error bars represent mean + SEM.
(G) CFU-C assay showing the number of colonies/AGM in E10.5 Cx3cr1+/+, Cx3cr1gfp/+, and Cx3cr1gfp/gfp embryos. BFU-E, burst forming unit-erythroid; CFU-G, CFU-granulocyte; CFU-M, CFU-macrophage; CFU-GM, CFU-granulocyte, macrophage; CFU-GEMM, CFU-granulocyte, erythrocyte, macrophage, megakaryocyte. Mean + SEM (n = 4).
(C and G) Student’s t test; (D–F) one-way Anova with Bonferroni correction. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. See Figure S5.
Figure 4Macrophages Co-localize and Interact with IAHCs
(A and B) Immunofluorescence (A) and time-lapse imaging extracted time points (B) of transversal sections (150 μm) of E10.5 MacGreen embryos. Macrophages, green; CD31+ endothelium, gray; c-Kit+ cells, blue. Scale bars, 20 μm.
(B–D) Time is indicated at the top of each image. White arrows indicate the macrophages entering the aorta (B) or interacting with IAHCs (A, C, D). See Videos S1, S2, and S3.
Figure 5AGM HS/PC Are Reduced upon Macrophage Depletion
(A) Experimental set-up. CFU-C, colony forming unit in culture; Tx, transplantation. Cytofluorimetric percentages of (B and E) viable cells and (C and F) macrophages in AGM explants treated with BLZ945 (0.67, 6.7, or 67 μM) or clodronate-liposomes compared to controls. Arrow, reduction in macrophage percentages upon treatment. (D and G) CFU-C numbers per AGM explant upon BLZ945 or clodronate-liposome treatment compared to control with percentage reduction shown. BFU-E, burst forming unit-erythroid; CFU-G, colony forming unit-granulocyte; CFU-M, colony forming unit-macrophage; CFU-GM, colony forming unit-granulocyte, macrophage; CFU-GEMM, colony forming unit-granulocyte, erythrocyte, macrophage, megakaryocyte. PBS-L, PBS-liposomes; Clod-L, clodronate-liposomes. In vivo transplantation of (H) BLZ945-treated and (I) clodronate-liposome-treated AGM explant cells into irradiated adult Ly5.1 recipients. Chimerism (%CD45.2+) in peripheral blood of recipients at 4 and 16 weeks post-transplant. Each symbol = one mouse. Triangles, BLZ945 or Clod-L treated AGMs; circles, controls (n = 3, Student’s t test). (B, C, D, F, G) Mean + SEM (n = 4). (H, I) The horizontal lines represent the mean. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. See Figure S6.
Figure 6Majority of E10.5 AGM Macrophages are CD206+
(A) Histograms (white), representative of 4 independent experiments, show percentages of AGM macrophages expressing Flk1, Tie2, IA/IE, and CD206 in E10.5 MacGreen embryos. FMO, gray.
(B) Time course of %CD206+ cells in E10–E11 MacGreen AGM. The data are represented as mean + SEM (n = 3).
(C) Rapid Romanowsky staining of cytospun E10.5 MacGreen (CD45+CD11b+F4/80+GFP+CD206+/−) macrophages. Left, GFP+CD206−; right, GFP+CD206+ cells. Scale bar, 20 μm. Black box separates cells from different slides. Number of vacuoles in CD206−GFP+ cells (white bars) and CD206+GFP+ macrophages (gray bars). 100–120 cells/population scored.
(D) Schematic of OP9-DL1 co-culture experiments (top). CD206−GFP+=GFP+CD45+CD206−; CD206+GFP+=GFP+CD45+CD206+; EC, endothelial cells (CD45−CD41−CD31+). Cell combinations plated on OP9-DL1 are indicated under the graph. Number of CFUs in culture (CFU-C) per 5×103 CD45+ cells. BFU-E, burst forming unit-erythroid; CFU-G, colony forming unit-granulocyte; CFU-M, colony forming unit-macrophage; CFU-GM, colony forming unit-granulocyte, macrophage; CFU-GEMM, colony forming unit-granulocyte, erythrocyte, macrophage, megakaryocyte.
(E) Total number of CD206−GFP+ and CD206+GFP+ cells/μm2 in non-hematopoietic trunk region (non-AGM) and AGM. n = 40 (10 random sections, 4 embryos), two-way ANOVA with multiple comparisons corrected by a Tukey’s range test, ∗∗∗p < 0.001. The data are represented as mean + SEM.
(F) Fluorescent image of a representative E10.5 MacGreen transverse section (10 μm) showing an AGM-associated macrophage (AGM-aM) along the aortic wall (left). Scale bar, 100 μm. Boxed area is enlarged on the right; scale bar, 20 μm. CD34, white; CD206, red; GFP, green; and DAPI, blue.
(G) Number of CFU-C per 5×103 CD45+ obtained after co-culturing CD206+GFP+ macrophages in contact with or separate from endothelial cells.
(D and G) mean + SEM (n = 4). Student’s t test, ∗p < 0.05, ∗∗p < 0.01.
Figure 7Transcriptomic Differences between CD206− and CD206+ AGM Cells
(A) Principal component analysis (PCA) on all expressed genes in GFP+CD206+ (green) and GFP+CD206− cells (purple) (n = 3, 4 AGMs/experiment).
(B–E) Heatmap calculated from the regularized log transformation counts of (B) the top 50 most variable genes, (C) cytokines, and (E) proteinases differentially expressed in GFP+CD206+ (green) and GFP+CD206− (purple) AGM populations. Samples are clustered using average linkage and Pearson correlation. Samples are vertical and genes horizontal; red = upregulated and blue = downregulated genes. Semi-quantitative RT-PCR (mean + SEM) of (D) inflammatory factors (n = 5, 3–4 AGM/experiment) and (F) Mmp9 (left) and Mmp13 (right) (n = 5) in E10.5 MacGreen GFP+CD206− and GFP+CD206+ cells. (D) Expression in CD206+ macrophages normalized over CD206− cells (horizontal line).
(F) Expression in CD206+ macrophages (gray) normalized over CD206− cells (white).
(D and F) Student’s t test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. See Tables S2 and S3.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Anti-Mouse CD41 (MWReg30)-143Nd | Fluidigm | Cat# 3143009C |
| Anti-Mouse CD45R/B220 (clone RA3-6B2)-144Nd | Fluidigm | Cat# 3144011C |
| Anti-Mouse CD43 (clone S11)-146Nd | Fluidigm | Cat# 3146009C |
| Anti-Mouse CD19 (clone 6D5)-149Sm | Fluidigm | Cat# 3149002C |
| Anti-Mouse CD64 (clone X54-5/7.1)-151Eu | Fluidigm | Cat# 3151012C |
| Anti-Mouse CD3e (clone 145-2C11)-152Sm | Fluidigm | Cat# 3152004C |
| Anti-Mouse CD16/32 (clone 93)-153Eu | Fluidigm | Cat# 3153011C |
| Anti-Mouse F4/80 (clone BM8)-159Tb | Fluidigm | Cat# 3159009C |
| Anti-Mouse CD11c (clone N418)-162Dy | Fluidigm | Cat# 3162017C |
| Anti-Mouse CD31/PECAM-1 (clone 390)-165Ho | Fluidigm | Cat# 3165013C |
| Anti-Mouse Nkp46 (clone 29A1.4)-167Er | Fluidigm | Cat# 3167008C |
| Anti-Mouse CD206/MMR (clone C068C2)-169Tm | Fluidigm | Cat# 3169021C |
| Anti-Mouse NK1.1 (clone PK136)-170Er | Fluidigm | Cat# 3170002C |
| Anti-Mouse CD11b (clone M1/70 )-172Yb | Fluidigm | Cat# 3172012C |
| Anti-Mouse CD117/c-kit (clone 2B8)-173Yb | Fluidigm | Cat# 3173004C |
| Anti-Mouse I-A/I-E (clone M5/144)-174Yb | Fluidigm | Cat# 3174003C |
| Anti-Mouse FceR1a (clone MAR-1)-176Yb | Fluidigm | Cat# 3176006C |
| FITC anti-Mouse/human CD45R/B220 (clone RA3-6B2) | BioLegend | Cat# 103205; RRID: |
| AF647 anti-Mouse CD192 (CCR2) (clone SA203G11) | BioLegend | Cat# 150603; RRID: |
| PE-Cy7 anti-Mouse CD193 (CCR3) (clone J073E5) | BioLegend | Cat# 144513; RRID: |
| PE anti-Mouse CD195 (CCR5) (clone HM-CCR5) | BioLegend | Cat# 107005; RRID: |
| BV421 anti-Mouse CD197 (CCR7) (clone 4B12) | BioLegend | Cat# 120119; RRID: |
| APC/Cy7 anti-Mouse/human CD11b (Mac1) (clone M1/70) | BioLegend | Cat# 101226; RRID: |
| APC anti-Mouse CD206 (mannose receptor) (clone C068C2) | BioLegend | Cat# 141707; RRID: |
| PE anti-mouse CD3 (clone 17A2) | BioLegend | Cat# 100205; RRID: |
| Alexa Fluor 647 anti-Mouse CD31 (clone MEC13.3) | BioLegend | Cat# 102516; RRID: |
| BV605 anti-Mouse CD31 (clone 390) | BioLegend | Cat# 102427; RRID: |
| Anti-Mouse CD34 biotin (clone RAM34) | eBioscience | Cat# 13-0341-82 |
| PE Rat anti-Mouse CD45 (clone 30-F11) | BD Biosciences | Cat# 553081; RRID: |
| BV650 anti-Mouse CD45 (clone 30-F11) | BD Horizon | Cat# 563410; RRID: |
| APC anti-Mouse CD45.1 (clone A20) | BD Biosciences | Cat# 558701; RRID: |
| PE anti-Mouse CD45.2 (clone 104) | BD Biosciences | Cat# 560695; RRID: |
| BV421 anti-Mouse CD117 (c-Kit) (clone 2B8) | BD Biosciences | Cat# 562609; RRID: |
| BV650 anti-Mouse CX3CR1 (clone SA011E11) | BioLegend | Cat# 149033; RRID: |
| PerCP-Cy5.5 anti-Mouse CD182 (CXCR2) (clone SA045E1) | BioLegend | Cat# 149605; RRID: |
| PE Dazzle594 anti-Mouse CD184 (CXCR4) (clone L276F12) | BioLegend | Cat# 146513; RRID: |
| PE-Cy5 anti-Mouse F4/80 (clone BM8) | eBioscience | Cat# 15-4801-80 |
| PerCP-Cy 5.5 anti-Mouse Flk-1 (clone AVAS12α1) | BD Pharmingen | Cat# 560681; RRID: |
| Anti-GFP | MBL | Cat# 598; RRID: |
| BV421 anti-Mouse I-A/I-E (clone M5/114.15.2) | BioLegend | Cat# 107631; RRID: |
| PE-CF594 anti-Mouse Ly-6C (clone AL-21) | BD Horizon | Cat# 562728; RRID: |
| AF700 anti-Mouse Ly-6G (clone 1A8) | BD Biosciences | Cat# 561236; RRID: |
| PE Cy7 anti-Mouse MerTK (clone DS5MMER) | eBioscience | Cat# 25-5751-80 |
| PE anti-Mouse CD202b (Tie2/Tek) (clone TEK4) | eBioscience | Cat# 12-5987 |
| Purified anti-mouse MerTK (clone DS5MMER) | eBioscience | Cat# 14-5751-82 |
| Purified anti-mouse Ly6C (MaxPar ready) (clone HK1.4) | BioLegend | Cat# 128039; RRID: |
| Purified anti-mouse Ly6G (MaxPar ready) (clone 1A8) | BioLegend | Cat# 127637; RRID: |
| Purified anti-mouse Siglec F (clone 1RNM44N) | eBioscience | Cat# 14-1702-82 |
| Collagenase from Clostridium histolyticum | Sigma-Aldrich | Cat# C0130; Lot# 02M1425V |
| RNeasy micro kit | Qiagen | Cat# 74004 |
| RNA-seq | This paper | GSE130579 |
| Mouse: OP9-DL1 | Obtained by Prof. Nancy Speck with permission from Zuniga-Plufcker | |
| Mouse: OP9 | ||
| Mouse: B6.Cg-Tg(Csf1r-EGFP)1Hume/J (also known as MacGreen) | The Jackson Laboratory | |
| Mouse: B6.129P2(Cg)- | The Jackson Laboratory | |
| Mouse: B6.Cg-Tg(Ly6a-EGFP)G5Dzk/J | The Jackson Laboratory | |
| Mouse: B6.SJL- | Charles River | |
| See | ||
| FastQC | FastQC: a quality control application for high throughput sequence data | |
| STAR (2.3) | ||
| Subread-FeatureCounts (1.5.2) | ||
| HiSat (2.0.4) | ||
| Prism Version 5 | GraphPad | |
| BD Facs Diva version 8 | BD Biosciences | |
| Image J | NIH | |
| Slidebook 6 | 3i | |
| FlowJo Version 8.7 and 10.1r5 | Tree Star, Inc | |
| MATLAB Version 2013b | N/A | |
| FlowSOM | Cytobank, Inc | |
| R coding for CyTOF analysis | This paper | |